Answer
Cholestyramine decreases mean exposure (AUC) to total ezetimibe, including ezetimibe glucuronide, by approximately 55%, potentially reducing the additional LDL-C lowering achieved by adding Nustendi to cholestyramine.
Sources for this answer
- Nustendi 180mg/10mg Film-coated TabletsDaiichi Sankyo UK Limited · emc · SmPC §4.5 Interaction with other medicinal products · Version 6Document updated
Sources checked